MIRM
Mirum Pharmaceuticals Inc
89.40$
+0.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 21.4% | 36.0% | 25.8% | 26.0% | 23.0% | 22.9% | 20.6% | 18.3% | 19.2% | 19.0% | 18.1% | 17.2% | 18.3% | |
| 78.6% | 64.0% | 74.2% | 74.0% | 77.0% | 77.1% | 79.4% | 81.7% | 80.8% | 81.0% | 81.9% | 82.8% | 81.7% | |
| 54.7% | 44.5% | 46.5% | 42.0% | 35.1% | 44.3% | 41.3% | 36.1% | 32.3% | 34.3% | 61.2% | 51.4% | 45.7% | |
| 76.5% | 57.3% | 65.9% | 53.0% | 55.9% | 45.6% | 51.7% | 49.5% | 46.5% | 49.8% | 60.3% | 46.2% | 50.8% | |
| 131.3% | 110.9% | 112.5% | 105.1% | 91.0% | 101.5% | 93.0% | 85.6% | 78.8% | 84.1% | 121.5% | 106.9% | 99.1% | |
| -52.7% | -46.8% | -38.2% | -31.1% | -14.0% | -24.4% | -13.6% | -3.9% | 2.0% | -3.1% | -39.5% | -24.1% | -17.4% | |
| 7.5% | 5.1% | 5.2% | 4.6% | 4.0% | 3.6% | 3.2% | 2.8% | 2.7% | 2.4% | 2.3% | 1.5% | 2.2% | |
| -48.9% | -50.9% | -35.6% | -30.8% | -15.4% | -24.5% | -12.2% | -4.3% | 2.0% | -3.3% | -493.9% | -37.2% | -138.7% | |
| 0.5% | 0.3% | 0.9% | 0.8% | 0.4% | -0.6% | 0.9% | 0.3% | -0.2% | 0.5% | 0.3% | 1.0% | 0.4% | |
| -49.4% | -51.3% | -36.5% | -31.6% | -15.8% | -23.9% | -13.2% | -4.6% | 2.2% | -3.8% | -494.2% | -38.1% | -139.2% | |
| -35.8% | -37.9% | -22.3% | -18.7% | -4.7% | -14.8% | -3.6% | 3.3% | 6.8% | 3.2% | -487.4% | -6.4% | -125.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.